Patents by Inventor Pedro J. Morales

Pedro J. Morales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEDIUM AND METHOD OF DERIVING AND USING A MUTATED BACTERIA STRAIN
    Publication number: 20120021004
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 26, 2012
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, John L. Alls, Pedro J. Morales
  • Medium and method of deriving and using a mutated bacteria strain
    Patent number: 8092988
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: January 10, 2012
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, John L. Alls, Pedro J. Morales, legal representative
  • Curlicue vaccine strain of
    Patent number: 7279320
    Abstract: A new strain of Bacillus anthracis derived from the Sterne vaccine strain of Bacillus anthracis by growth on a high-nitrate-concentration, 3-amino-L-tyrosine growth medium.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: October 9, 2007
    Assignee: United States as represented by the Secretary of the Air Force
    Inventors: Jill E. Parker, Johnathan L. Kiel, Homer Gifford, Pedro J. Morales, legal representative, John L. Alls, deceased
  • Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
    Publication number: 20040044182
    Abstract: Methods of producing and using recombinant soluble HLA-G are provided. This recombinant soluble HLA-G alters immune responses to tissues, organs, fetuses, and embryos which are genetically distinct from the organism receiving or possessing such antigenic material. Preferable forms of this protein include sequences having at least 70% sequence homology with naturally occurring forms of HLA-G. Specifically, each recombinant form of HLA-G produced and used by the present methods must include a sequence having at least 70% sequence homology to introm 4 expressed by the HLA-G gene and at least one sequence having at least 70% sequence homology to one of the &agr; domains expressed by the HLA-G gene. Preferable forms of the present invention include one isoform which includes the &agr;1 domain, the &agr;2 domain, the &agr;3 domain, and intron 4, and a second isoform which includes the &agr;1 domain, the &agr;3 domain and intron 4.
    Type: Application
    Filed: July 28, 2003
    Publication date: March 4, 2004
    Inventors: Joan S Hunt, Pedro J. Morales, Margaret G. Pertroff